Corticosteriod Therapy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

J Korean Neurol Assoc > Volume 6(2); 1988 > Article

Journal of the Korean Neurological Association 1988;6(2): 129-138.

만성 염증성 탈수초성 신경병증(CIDP) 에서의 스테로이트 약물효과`

이광우, 이상우, 명호진, 지제근

서울대학교 신경과, 병리과.

Corticosteriod Therapy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Kwang-Woo Lee, M.D., Sang-Bok Lee, M.D., and Ho-Jin Myung, M.D., Je-Geun Chi, M.D.

Department of Neurology, College of Medicine, Seoul National University Department of Pathology, College of Medicine, Seoul National University

Abstract

Since the clinical features were first delineated in 1975 by Dyck et al, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been clearly recognized as a separate clinical entity. The diagnosis of CIDP can be made when there are a symmetrical motor & sensory polyneuropathy with chronic progression, high CSF protein level and marked nerve conduction abnormalities of demyelinating type, which occur in the absence of associated illness. From July 1985 to June 1987, authors have observed seven cases of CIDP. Prednisone was begun at a daily dosage of 1-2mg per kg when each patient fulfilled the above described critera. Significant clinical improvement was recorded in six out of seven cases within four weeks after initiation of corticosteriod therapy. In one case dramatic relief of tingling sensation was observed within 5th day, but motor power improved gradually during the sixth to eighth weeks of daily theapy. No significant side effects of prednisone was found in all cases except for one, who suffered from compressed fracture of lumbar vertebra with minor physical trauma. Therefore it could be concluded that corticosteriod therapy seems to have beneficial effect on patients with severe degree of CIDP.